[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05772845":3,"trial-entities:NCT05772845":231,"trial-summary:NCT05772845":236},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":25,"interventions":28,"primary_outcomes":41,"secondary_outcomes":170,"sex":186,"minimum_age":187,"maximum_age":188,"healthy_volunteers":189,"eligibility_criteria":190,"std_ages":205,"locations":207,"central_contacts":223,"overall_officials":226,"references":229,"see_also_links":230},"NCT05772845","STUDY00006122","Vaping and Smoking Withdrawal Project","A Controlled Evaluation of Abstinence-Induced Withdrawal and Motivation to Vape\u002FSmoke Among Daily ENDS Users vs. Cigarette Smokers","RECRUITING","2026-11-30","2026-03","2026-03-09","2023-02-14","State University of New York at Buffalo","OTHER",false,"The proposed research, which will systematically and comprehensively characterize the withdrawal among daily vapers compared to daily smokers of combustible cigarettes, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence\u002Fabuse liability and contributing to the development of therapies for tobacco\u002Fnicotine use, the leading preventable cause of death in the US.","Withdrawal is a key, multi-faceted component of tobacco\u002Fnicotine dependence. Because withdrawal symptoms are theorized to drive relapse, facets of withdrawal (e.g., craving, negative affect) are the targets of most current and emerging treatments. Despite the central importance of withdrawal, and a voluminous literature on withdrawal from combustible cigarette smoking, little is known about withdrawal from electronic nicotine delivery systems (ENDS). To overcome critical barriers to progress in the field, the first-ever prospective, controlled comparison of abstinence-induced withdrawal between ENDS vapers and cigarette smokers is proposed. Participants will be 160 established daily vapers (including former smokers and dual users who smoke occasionally), 160 established daily smokers (including former vapers and dual users who vape occasionally), and (for exploratory comparisons) 50 established daily dual users, who smoke and vape daily. Participants will complete two 4-hour lab visits; the order of the ad lib use visit and the abstinent visit (which follows 24 hours of abstinence) will be randomized across participants. To advance knowledge of ENDS withdrawal, state-of-the-science, multi-measure, multi-method assessments of key withdrawal facets (negative affect, craving, difficulty concentrating, restlessness, sleep, and appetite, as well as anhedonia\u002Fpositive affect and somatic effects) will be employed. For each facet, the hypothesis that withdrawal magnitude is lower among vapers compared to smokers will be tested. To inform theory and intervention development, the behavioral significance of ENDS withdrawal will also be evaluated, testing the hypotheses that abstinence will increase the motivation to vape\u002Fsmoke and this group difference will be accounted for (mediated) by vaper\u002Fsmoker differences in one or more withdrawal facets. Exploratory analyses will examine whether group differences in withdrawal are accounted for (mediate) by differential nicotine exposure, explore the role of individual differences (e.g., sex, rate of nicotine metabolism, expectancies), and examine differences among sub-groups of vapers. The impact of this much-needed, detailed characterization of withdrawal from ENDS is enhanced by the inclusion of a comparator of great public health significance, cigarette smoking. In addition, by characterizing the specific withdrawal facets that drive motivation to vape\u002Fsmoke, the proposed work will identify promising intervention targets for subsequent treatment development efforts.",[19],"Acute Abstinence From Cigarettes vs E-cigarettes (ENDS)",[],"INTERVENTIONAL","BASIC_SCIENCE",[24],"NA",{"count":26,"type":27},370,"ESTIMATED",[29,37],{"type":30,"name":31,"description":32,"armGroupLabels":33},"BEHAVIORAL","Acute (24-hour) abstinence","Participants will be asked to abstain from all tobacco\u002Fnicotine for 24 hours prior to the visit",[34,35,36],"Daily Dual Users of ENDS and Combustible Cigarettes","Daily Users of Combustible Cigarettes","Daily Users of ENDS",{"type":30,"name":38,"description":39,"armGroupLabels":40},"Ad libitum smoking\u002Fvaping","Participants will be asked to smoke\u002Fvape as usual during the 24 hours prior to the visit",[34,35,36],[42,46,49,52,54,57,59,62,64,67,69,72,74,77,79,82,84,87,89,92,94,97,99,102,104,106,108,111,113,116,118,121,123,127,130,133,137,140,143,146,148,150,151,153,155,158,161,164,167],{"measure":43,"description":44,"timeFrame":45},"Wisconsin Smoking Withdrawal Scale - anger 0.5","anger subscale score","0.5 hours",{"measure":47,"description":44,"timeFrame":48},"Wisconsin Smoking Withdrawal Scale - anger 2.5","2.5 hours",{"measure":50,"description":51,"timeFrame":45},"Wisconsin Smoking Withdrawal Scale - anx 0.5","anxiety subscale score",{"measure":53,"description":51,"timeFrame":48},"Wisconsin Smoking Withdrawal Scale - anx 2.5",{"measure":55,"description":56,"timeFrame":45},"Wisconsin Smoking Withdrawal Scale - sad 0.5","sadness subscale score",{"measure":58,"description":56,"timeFrame":48},"Wisconsin Smoking Withdrawal Scale - sad 2.5",{"measure":60,"description":61,"timeFrame":45},"Wisconsin Smoking Withdrawal Scale - conc 0.5","difficulty concentrating subscale score",{"measure":63,"description":61,"timeFrame":48},"Wisconsin Smoking Withdrawal Scale - conc 2.5",{"measure":65,"description":66,"timeFrame":45},"Wisconsin Smoking Withdrawal Scale - sleep 0.5","sleep subscale score",{"measure":68,"description":66,"timeFrame":48},"Wisconsin Smoking Withdrawal Scale - sleep 2.5",{"measure":70,"description":71,"timeFrame":45},"Wisconsin Smoking Withdrawal Scale - appetite 0.5","appetite subscale score",{"measure":73,"description":71,"timeFrame":48},"Wisconsin Smoking Withdrawal Scale - appetite 2.5",{"measure":75,"description":76,"timeFrame":45},"Mood and Physical Symptoms Scale - 0.5","single-item indicators of withdrawal facets",{"measure":78,"description":76,"timeFrame":48},"Mood and Physical Symptoms Scale - 2.5",{"measure":80,"description":81,"timeFrame":45},"Minnesota Nicotine Withdrawal Scale - 0.5","17-item version with indicators of various withdrawal facets",{"measure":83,"description":81,"timeFrame":48},"Minnesota Nicotine Withdrawal Scale - 2.5",{"measure":85,"description":86,"timeFrame":45},"Positive and Negative Affect Scale - PA 0.5","positive affect subscale score",{"measure":88,"description":86,"timeFrame":48},"Positive and Negative Affect Scale - PA 2.5",{"measure":90,"description":91,"timeFrame":45},"Positive and Negative Affect Scale - NA 0.5","negative affect subscale score",{"measure":93,"description":91,"timeFrame":48},"Positive and Negative Affect Scale - NA 2.5",{"measure":95,"description":96,"timeFrame":45},"Snaith-Hamilton Pleasure Scale 0.5","total score",{"measure":98,"description":96,"timeFrame":48},"Snaith-Hamilton Pleasure Scale 2.5",{"measure":100,"description":101,"timeFrame":45},"Questionnaire on Vaping Craving 0.5","total craving score",{"measure":103,"description":101,"timeFrame":48},"Questionnaire on Vaping Craving 2.5",{"measure":105,"description":101,"timeFrame":45},"Questionnaire on Smoking Urges - Brief 0.5",{"measure":107,"description":101,"timeFrame":48},"Questionnaire on Smoking Urges - Brief 2.5",{"measure":109,"description":110,"timeFrame":45},"PhenX Toolkit Insomnia Severity Index 0.5","7-item scale (but item #5 is omitted because of the short time-frame), total score impairment and interference with daily functioning",{"measure":112,"description":110,"timeFrame":48},"PhenX Toolkit Insomnia Severity Index 2.5",{"measure":114,"description":115,"timeFrame":45},"Restlessness ratings 0.5","3-item scale",{"measure":117,"description":115,"timeFrame":48},"Restlessness ratings 2.5",{"measure":119,"description":120,"timeFrame":45},"Restlessness and Agitation Questionnaire - Modified 0.5","total score on subset of behavioral indicators",{"measure":122,"description":120,"timeFrame":48},"Restlessness and Agitation Questionnaire - Modified 2.5",{"measure":124,"description":125,"timeFrame":126},"Identical Pair Continuous Performance Task","Sustained attention, or vigilance, is the ability to maintain alertness to detect infrequent target stimuli during a long, monotonous task (e.g., Mackworth, 1948). We will use a version of the identical-pairs continuous performance task (Cornblatt et al., 1988) in which participants attend to a series of 800 4-digit numbers on a computer monitor (100-ms stimulus duration; 1500-ms ISI).\n\nParticipants are asked to press the keyboard space bar only when the stimulus is identical to the immediately preceding stimulus (10% targets; Cooper et al., 2020; Rhodes \\& Hawk, 2016).\n\nPercent correct hits (target detections) is the primary outcome.","~2 hours",{"measure":128,"description":129,"timeFrame":126},"n-back working memory task","The n-back task (e.g., Strand et al., 2012; Rhodes \\& Hawk, 2016) requires indicating whether each stimulus in a rapidly presented series matches the location of the stimulus presented n stimuli before (e.g., n=0,1,2). Stimuli are small grey circles (100 ms; 30% targets). The focus here is on conditions that place marked demands on the \"central executive\" by requiring ongoing mental manipulation (i.e., n=2; see Baddeley, 2003). Brief practice with a 1-back and 2-back will be followed by 2 100-trial blocks of the 2-back. Accuracy is the primary outcome.",{"measure":131,"description":132,"timeFrame":126},"Stop signal reaction time task","We will employ the stop-signal paradigm (Logan et al., 1984), which provides a relatively pure index response inhibition (e.g., Nigg, 2001). In our typical task (e.g., Hawk et al., 2018; Rhodes \\& Hawk, 2016), participants button press to indicate whether the \"go\" signal (\\\u003C-- or --\\>) is pointing left or right. After a brief \"go\" practice, the stop signal (100-ms tone) is introduced, and participants complete 3 64-trail bocks during with they are asked to respond as quickly as possible but to not respond on stop signal trials (25% of trials). The stop signal occurs after go signal onset and adjusts dynamically across trials to yield \\~50% inhibition (Logan et al., 1997). The primary outcome is stop signal reaction time (SSRT), an estimate of the speed of inhibition.",{"measure":134,"description":135,"timeFrame":136},"kcal consumed","Fat, protein, and carbohydrate calories, and total calories, consumed during the visit.","3 hours",{"measure":138,"description":139,"timeFrame":45},"Hypothetical commodity purchase task - vaping intensity 0.5","Intensity of demand",{"measure":141,"description":142,"timeFrame":48},"Hypothetical commodity purchase task - vaping intensity 2.5","intensity of demand",{"measure":144,"description":145,"timeFrame":45},"Hypothetical commodity purchase task - vaping persistence 0.5","persistence of demand",{"measure":147,"description":145,"timeFrame":48},"Hypothetical commodity purchase task - vaping persistence 2.5",{"measure":149,"description":142,"timeFrame":45},"Hypothetical commodity purchase task - smoking intensity 0.5",{"measure":149,"description":142,"timeFrame":48},{"measure":152,"description":145,"timeFrame":45},"Hypothetical commodity purchase task - smoking persistence 0.5",{"measure":154,"description":145,"timeFrame":48},"Hypothetical commodity purchase task - smoking persistence 2.5",{"measure":156,"description":157,"timeFrame":136},"Choice Behavior Under Cued Conditions (CBUCC) Task - spend vape","Spending for vape puffs",{"measure":159,"description":160,"timeFrame":136},"Choice Behavior Under Cued Conditions (CBUCC) Task - spend cig","Spending for cigarette puffs",{"measure":162,"description":163,"timeFrame":136},"Choice Behavior Under Cued Conditions (CBUCC) Task - spend water","Spending for water control",{"measure":165,"description":166,"timeFrame":136},"Choice Behavior Under Cued Conditions (CBUCC) Task - crave vape","Craving for vape puffs",{"measure":168,"description":169,"timeFrame":136},"Choice Behavior Under Cued Conditions (CBUCC) Task - crave cig","Craving for cigarette puffs",[171,175,178,182,185],{"measure":172,"description":173,"timeFrame":174},"modified Cigarette evaluation questionnaire","subjective\u002Fsensory aspects of smoking","3.5 hours",{"measure":176,"description":177,"timeFrame":174},"modified e-Cigarette evaluation questionnaire","subjective\u002Fsensory aspects of vaping",{"measure":179,"description":180,"timeFrame":181},"Heart rate","Heart rate, in beats per minute","assessed at ~30-minute intervals",{"measure":183,"description":184,"timeFrame":45},"Somatic\u002Fside effect checklist","Assesses a range of somatic and psychological symptoms (e.g., headache, fatigue, anxiety)",{"measure":183,"description":184,"timeFrame":48},"ALL","21 Years","50 Years",true,{"inclusion":191,"exclusion":194,"raw_text":204},[192,193],"6+ months of daily\u002Fnear-daily nicotine vaping and\u002For cigarette smoking (to yield 160 vapers, 160 smokers, 50 dual users)","200+ ng\u002FmL cotinine on a commercially-available quick screen",[195,196,197,198,199,200,201,202,203],"intention to quit daily\u002Fnear-daily vaping\u002Fsmoking in the next month","current (2+ days out of the past 7) use of pipe tobacco, hookah\u002Fshisha, smokeless tobacco, dissolvable tobacco, nicotine pouches. For vaping group only, current (2+ days out of past 7) use of cigars, cigarillos, or filtered cigars that are filled with tobacco or a mix of tobacco and marijuana","current use of any smoking cessation medication","current severe substance dependence other than tobacco\u002Fnicotine (including cannabis; NIDA Modified ASSIST of 27+)","current (past 2 weeks) suicidal ideation with intent and\u002For plan","current antipsychotic medications or lifetime history of schizophrenia or bipolar disorder","pregnancy (intake urine screen)","alcohol: AUDIT \\> 15 for males and \\>13 for females (eliminated 7\u002F25\u002F23)","current major depression (PHQ-9\\>11) (eliminated 7\u002F25\u002F23)","Inclusion Criteria:\n\n* 6+ months of daily\u002Fnear-daily nicotine vaping and\u002For cigarette smoking (to yield 160 vapers, 160 smokers, 50 dual users)\n* 200+ ng\u002FmL cotinine on a commercially-available quick screen\n\nCurrent Exclusion Criteria:\n\n* intention to quit daily\u002Fnear-daily vaping\u002Fsmoking in the next month\n* current (2+ days out of the past 7) use of pipe tobacco, hookah\u002Fshisha, smokeless tobacco, dissolvable tobacco, nicotine pouches. For vaping group only, current (2+ days out of past 7) use of cigars, cigarillos, or filtered cigars that are filled with tobacco or a mix of tobacco and marijuana\n* current use of any smoking cessation medication\n* current severe substance dependence other than tobacco\u002Fnicotine (including cannabis; NIDA Modified ASSIST of 27+)\n* current (past 2 weeks) suicidal ideation with intent and\u002For plan\n* current antipsychotic medications or lifetime history of schizophrenia or bipolar disorder\n* pregnancy (intake urine screen)\n\nOriginal Exclusion Criteria that have been modified or eliminated:\n\n* \\>1 use in past month of tobacco\u002Fnicotine products other than ENDS and combustible cigarettes (modified 5\u002F19\u002F25 - see current exclusion criteria)\n* alcohol: AUDIT \\> 15 for males and \\>13 for females (eliminated 7\u002F25\u002F23)\n* current major depression (PHQ-9\\>11) (eliminated 7\u002F25\u002F23)\n* suicide risk (answer to question #9 on PHQ-9 is anything other than \"Not at all\") (modified 11\u002F17\u002F23 - see current exclusion criteria)",[206],"ADULT",[208],{"facility":209,"status":8,"city":210,"state":211,"zip":212,"country":213,"contacts":214,"geoPoint":220},"University at Buffalo","Buffalo","New York","14260","United States",[215],{"name":216,"role":217,"phone":218,"email":219},"Larry Hawk, PhD","CONTACT","7166450192","lhawk@buffalo.edu",{"lat":221,"lon":222},42.88645,-78.87837,[224],{"name":216,"role":217,"phone":225,"email":219},"716-645-0192",[227],{"name":216,"affiliation":209,"role":228},"PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":232,"biomarkers":234},[233],"Tobacco dependence syndrome",[235],"Cotinine",{"nct_id":4,"found":189,"summary":237,"prompt_version":246},{"design":238,"status":239,"heading":6,"summary":240,"follow_up":241,"word_count":242,"commitments":243,"compensation":244,"drugs_mentioned":245},"This interventional study plans to enroll 370 participants, including vapers, smokers, and dual users. Participants will be randomly assigned to the order of their study visits.","completed","This study is looking at the differences in withdrawal symptoms between people who vape (use e-cigarettes) and people who smoke regular cigarettes. Researchers want to understand how the body reacts when someone stops using nicotine from either vaping or smoking. You might be able to join if you are between 21 and 50 years old and have been vaping or smoking daily for at least six months. To be eligible, a quick test will confirm you have a certain level of nicotine in your system (200+ ng\u002FmL cotinine). The study will compare how anger and anxiety change after a short period without nicotine. This research aims to help develop better ways to treat nicotine addiction.","Your withdrawal symptoms will be measured at 0.5 hours and 2.5 hours during the study visits.",115,"You will complete two 4-hour lab visits. One visit will follow 24 hours of not using any tobacco\u002Fnicotine, and the other will follow 24 hours of smoking\u002Fvaping as usual.","Not stated in the trial record.",[],"v2"]